Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study

Adel GabrielDepartments of Psychiatry and Community Health Sciences, University of Calgary, Alberta, CanadaBackground: There is a great need in the treatment of schizophrenia for a drug, or drug &shy;combinations, to improve clinical response with fewer serious side effects. The objective of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Adel Gabriel
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a5e815c9d82c4d108cdb1a65f8460937
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a5e815c9d82c4d108cdb1a65f8460937
record_format	dspace
spelling	oai:doaj.org-article:a5e815c9d82c4d108cdb1a65f84609372021-12-02T02:08:36ZGabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study1176-63281178-2021https://doaj.org/article/a5e815c9d82c4d108cdb1a65f84609372010-10-01T00:00:00Zhttp://www.dovepress.com/gabapentin-adjunctive-to-risperidone-or-olanzapine-in-partially-respon-a5571https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Adel GabrielDepartments of Psychiatry and Community Health Sciences, University of Calgary, Alberta, CanadaBackground: There is a great need in the treatment of schizophrenia for a drug, or drug &shy;combinations, to improve clinical response with fewer serious side effects. The objective of this study was to explore the therapeutic effects and tolerability of the anticonvulsant gabapentin as an adjunctive in the treatment of patients with partially responsive schizophrenia.Methods: Ten consenting patients with a confirmed Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision diagnosis of schizophrenia were identified. All patients failed at least one 12-week treatment trial with risperidone or olanzapine. Gabapentin was added to ongoing antipsychotic treatment with olanzapine or risperidone for eight weeks. The primary outcome measure was the Positive and Negative Syndrome Scale (PANSS). Other scales included the Calgary Depression Scale (CDSS) and the Abnormal Involuntary Movement Scale (AIMS). Repeated-measures multivariate analysis of variance was utilized to examine changes in outcome measures over time with adjunctive treatment with gabapentin.Results: There was a significant drop in the PANSS and CDSS scores at endpoint (week 8). There were no significant differences between the two treatment groups with regard to changes in all outcome measures or in AIMS score. The adjunctive treatments were well tolerated and side effects were transient.Conclusion: Gabapentin could be used successfully as an adjunct to novel antipsychotics in partially responsive schizophrenia. However, large controlled studies are needed to examine the effectiveness of gabapentin in psychotic disorders.Keywords: schizophrenia, refractory, adjunctive treatment, gabapentin, risperidone, olanzapine Adel GabrielDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 711-717 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Adel Gabriel Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
description	Adel GabrielDepartments of Psychiatry and Community Health Sciences, University of Calgary, Alberta, CanadaBackground: There is a great need in the treatment of schizophrenia for a drug, or drug &shy;combinations, to improve clinical response with fewer serious side effects. The objective of this study was to explore the therapeutic effects and tolerability of the anticonvulsant gabapentin as an adjunctive in the treatment of patients with partially responsive schizophrenia.Methods: Ten consenting patients with a confirmed Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision diagnosis of schizophrenia were identified. All patients failed at least one 12-week treatment trial with risperidone or olanzapine. Gabapentin was added to ongoing antipsychotic treatment with olanzapine or risperidone for eight weeks. The primary outcome measure was the Positive and Negative Syndrome Scale (PANSS). Other scales included the Calgary Depression Scale (CDSS) and the Abnormal Involuntary Movement Scale (AIMS). Repeated-measures multivariate analysis of variance was utilized to examine changes in outcome measures over time with adjunctive treatment with gabapentin.Results: There was a significant drop in the PANSS and CDSS scores at endpoint (week 8). There were no significant differences between the two treatment groups with regard to changes in all outcome measures or in AIMS score. The adjunctive treatments were well tolerated and side effects were transient.Conclusion: Gabapentin could be used successfully as an adjunct to novel antipsychotics in partially responsive schizophrenia. However, large controlled studies are needed to examine the effectiveness of gabapentin in psychotic disorders.Keywords: schizophrenia, refractory, adjunctive treatment, gabapentin, risperidone, olanzapine
format	article
author	Adel Gabriel
author_facet	Adel Gabriel
author_sort	Adel Gabriel
title	Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
title_short	Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
title_full	Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
title_fullStr	Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
title_full_unstemmed	Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
title_sort	gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/a5e815c9d82c4d108cdb1a65f8460937
work_keys_str_mv	AT adelgabriel gabapentinadjunctivetorisperidoneorolanzapineinpartiallyresponsiveschizophreniaanopenlabelpilotstudy
_version_	1718402666752638976

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study

Ejemplares similares